Summary:
A Phase 2a Study to evaluate the safety, tolerability and initial efficacy of pramipexole IR, given with ondansetron in patients with major depressive disorder
Qualified Participants Must:
• Males and females aged between 18 and 65 years inclusive
•
Patients who are currently not on any antidepressants or patients on antidepressants and agree to the appropriate washout period
Qualified Participants May Receive:
Compensation for time and travel.